EGRIFTA WR

(tesamorelin)

ApprovedSmall molecule

TTheratechnologies

EGRIFTA WR is one of 288 small molecule programs targeting Lipodystrophy. It is currently in Approved.

Indications

Total Trials

Active Trials

287

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

LipodystrophyActive, not recruiting

Alcoholic Fatty Liver DiseaseActive, not recruiting

Brain InjuryActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

CognitionActive, not recruiting

Sleep DisorderActive, not recruiting

Fatty Liver DiseaseActive, not recruiting

ObesityActive, not recruiting

Diabetic RetinopathyActive, not recruiting

GrowthActive, not recruiting

LipodystrophyPhase 3

Active, not recruiting

Alcoholic Fatty Liver DiseasePhase 2

Active, not recruiting

Brain InjuryPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

CognitionPhase 2

Active, not recruiting

Sleep DisorderPreclinical

Active, not recruiting

Fatty Liver DiseasePhase 2

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Diabetic RetinopathyApproved

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

EGRIFTA WR

TTheratechnologies

Approved

1 2

Veramyst

GSK

Preclinical

26 3

Flovent

GSK

Preclinical

6 4

Spiriva

Boehringer Ingelheim

Preclinical

15 5

Aclidinium Bromide

AstraZeneca

Preclinical

21 6

Atrovent

Boehringer Ingelheim

Preclinical

5 7

Calciferol

Alnylam Pharmaceuticals

Duragesic

2 9

Narcan

SScienture

Preclinical

1 10

Coumadin

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Fatty Liver Disease

NCT07481734

Q2 2028

Phase 2Recruiting

Function

NCT06554717

Clinical

Trials by Indication[1]

Growth2 trials

Effects of Growth Hormone Releasing Hormone in HIV

Completed·MMassachusetts General Hospital·N/A·NCT01263717·54 enrolled

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

Completed·TTheratechnologies·Phase 1·NCT02012556·18 enrolled

HIV1 trial

Body Composition and Adipose Tissue in HIV

Completed·—·Phase 4·NCT03226821·5 enrolled

Function1 trial

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

Recruiting·MMassachusetts General Hospital·Phase 2·NCT06554717·100 enrolled

Lipodystrophy1 trial

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Completed·TTheratechnologies·Phase 3·NCT00608023·263 enrolled

Alcoholic Fatty Liver Disease1 trial

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Completed·MMassachusetts General Hospital·Phase 2·NCT03375788·51 enrolled

8 more indications

Liver1 trial

Tesamorelin Effects on Liver Fat and Histology in HIV

Completed·MMassachusetts General Hospital·N/A·NCT02196831·61 enrolled

Obesity1 trial

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

Withdrawn·MMassachusetts General Hospital·N/A·NCT01632592

Chronic Obstructive Pulmonary Disease1 trial

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

Terminated·TTheratechnologies·Phase 2·NCT01388920·3 enrolled

Cognition1 trial

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

Completed·UUniversity of California, San Diego·Phase 2·NCT02572323·73 enrolled

Brain Injury1 trial

Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

Withdrawn·NNational Institute of Nursing Research (NINR)·Phase 2·NCT02931474

Fatty Liver Disease1 trial

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

Recruiting·HHudson Biotech·Phase 2·NCT07481734·120 enrolled

Diabetic Retinopathy1 trial

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Terminated·TTheratechnologies·Phase 4·NCT01591902·129 enrolled

Sleep Disorder1 trial

Egrifta Replacement and Sleep Disordered Breathing

Withdrawn·JJohns Hopkins University··NCT01788462

Regulatory

FDA Approval Timeline[4]

Nov 10, 2010

EGRIFTA WR

BLA BLA022505

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for tesamorelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tesamorelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tesamorelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA022505). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Theratechnologies company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTheratechnologies

EGRIFTA WR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Trials by Indication[1]

Growth2 trials

HIV1 trial

Function1 trial

Lipodystrophy1 trial

Alcoholic Fatty Liver Disease1 trial

Liver1 trial

Obesity1 trial

Chronic Obstructive Pulmonary Disease1 trial

Cognition1 trial

Brain Injury1 trial

Fatty Liver Disease1 trial

Diabetic Retinopathy1 trial

Sleep Disorder1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News